Wellcome Trust/MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Cambridge, UK; Liver Unit, Cambridge NIHR Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Gastroenterology and Hepatology, Norfolk and Norwich University Hospitals, Norwich, UK.
Wellcome Trust/MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Cambridge, UK; Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK; Clinica Medica Cesare Frugoni, Department of Interdisciplinary Medicine, University of Bari Aldo Moro, Bari, Italy.
Mol Metab. 2021 Jun;48:101210. doi: 10.1016/j.molmet.2021.101210. Epub 2021 Mar 17.
Non-alcoholic fatty liver disease (NAFLD) is a silent pandemic associated with obesity and the metabolic syndrome, and also increases cardiovascular- and cirrhosis-related morbidity and mortality. A complete understanding of adaptive compensatory metabolic programmes that modulate non-alcoholic steatohepatitis (NASH) progression is lacking.
Transcriptomic analysis of liver biopsies in patients with NASH revealed that NASH progression is associated with rewiring of metabolic pathways, including upregulation of de novo lipid/cholesterol synthesis and fatty acid remodelling. The modulation of these metabolic programmes was achieved by activating sterol regulatory element-binding protein (SREBP) transcriptional networks; however, it is still debated whether, in the context of NASH, activation of SREBPs acts as a pathogenic driver of lipotoxicity, or rather promotes the biosynthesis of protective lipids that buffer excessive lipid accumulation, preventing inflammation and fibrosis. To elucidate the pathophysiological role of SCAP/SREBP in NASH and wound-healing response, we used an Insig1 deficient (with hyper-efficient SREBPs) murine model challenged with a NASH-inducing diet. Despite enhanced lipid and cholesterol biosynthesis, Insig1 KO mice had similar systemic metabolism and insulin sensitivity to Het/WT littermates. Moreover, activating SREBPs resulted in remodelling the lipidome, decreased hepatocellular damage, and improved wound-healing responses.
Our study provides actionable knowledge about the pathways and mechanisms involved in NAFLD pathogenesis, which may prove useful for developing new therapeutic strategies. Our results also suggest that the SCAP/SREBP/INSIG1 trio governs transcriptional programmes aimed at protecting the liver from lipotoxic insults in NASH.
非酒精性脂肪性肝病(NAFLD)是一种与肥胖和代谢综合征相关的无声流行疾病,也会增加心血管疾病和肝硬化相关的发病率和死亡率。目前对于调节非酒精性脂肪性肝炎(NASH)进展的适应性代偿性代谢方案还缺乏全面了解。
对 NASH 患者肝活检的转录组分析表明,NASH 进展与代谢途径的重新布线有关,包括从头合成脂质/胆固醇和脂肪酸重塑的上调。这些代谢方案的调节是通过激活固醇调节元件结合蛋白(SREBP)转录网络来实现的;然而,在 NASH 的背景下,SREBPs 的激活是否作为脂毒性的致病驱动因素,或者是否促进了缓冲过量脂质积累、预防炎症和纤维化的保护性脂质的生物合成,这仍存在争议。为了阐明 SCAP/SREBP 在 NASH 和伤口愈合反应中的病理生理作用,我们使用 Insig1 缺失(具有高效 SREBPs)的小鼠模型进行了 NASH 诱导饮食挑战。尽管脂质和胆固醇的生物合成增强,但 Insig1 KO 小鼠的全身代谢和胰岛素敏感性与 Het/WT 同窝仔相似。此外,激活 SREBPs 导致脂质组重塑、减少肝细胞损伤,并改善伤口愈合反应。
我们的研究提供了有关 NAFLD 发病机制涉及的途径和机制的可操作知识,这可能对开发新的治疗策略有用。我们的结果还表明,SCAP/SREBP/INSIG1 三胞胎控制着旨在保护肝脏免受 NASH 中脂毒性损伤的转录程序。